Proteomics and translational medicine: molecular biomarkers for cancer diagnosis, prognosis and prediction of therapy outcome

References

• Cho WC. Conquering cancer through discovery research. IUBMB Life62(9), 655–659 (2010).
   PubMed Web of Science ®Google Scholar
• Cho WC. Molecular diagnostics for monitoring and predicting therapeutic effect in cancer. Expert Rev. Mol. Diagn.11(1), 9–12 (2011).
   PubMed Web of Science ®Google Scholar
• Cho WC. Cancer biomarkers (an overview). In: Methods of Cancer Diagnosis, Therapy and Prognosis (Volume 7). Hayat MA (Ed.). Springer, Berlin, Germany, 21–40 (2010).
   Google Scholar
• Cho WC, Cheng CH. Oncoproteomics: current trends and future perspectives. Expert Rev. Proteomics4(3), 401–410 (2007).
   PubMed Web of Science ®Google Scholar
• Sun S, Poon RT, Lee NP et al. Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (< or = 2 cm). J. Proteome Res.9(4), 1923–1930 (2010).
   PubMed Web of Science ®Google Scholar
• Yeo M, Na YM, Kim DK et al. The loss of phenol sulfotransferase 1 in hepatocellular carcinogenesis. Proteomics10(2), 266–276 (2010).
   PubMedGoogle Scholar
• Farlow EC, Patel K, Basu S et al. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin. Cancer Res.16(13), 3452–3462 (2010).
   PubMedGoogle Scholar
• Chen YT, Chen CL, Chen HW et al. Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology. J. Proteome Res.9(11), 5803–5815 (2010).
   PubMed Web of Science ®Google Scholar
• Fung ET. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin. Chem.56(2), 327–329 (2010).
   PubMed Web of Science ®Google Scholar
• Chung KH, Lee DH, Kim Y et al. Proteomic identification of overexpressed PRDX 1 and its clinical implications in ovarian carcinoma. J. Proteome Res.9(1), 451–457 (2010).
   PubMed Web of Science ®Google Scholar
• Moreira JM, Ohlsson G, Gromov P et al. Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. Mol. Cell. Proteomics9(1), 161–177 (2010).
   PubMed Web of Science ®Google Scholar
• Dos Santos A, Court M, Thiers V et al. Identification of cellular targets in human intrahepatic cholangiocarcinoma using laser microdissection and accurate mass and time tag proteomics. Mol. Cell. Proteomics9(9), 1991–2004 (2010).
   PubMedGoogle Scholar
• Bouamrani A, Ramus C, Gay E et al. Increased phosphorylation of vimentin in noninfiltrative meningiomas. PLoS One5(2), e9238 (2010).
   PubMed Web of Science ®Google Scholar
• Cho WC, Yip TT, Cheng WW et al. Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis. Br. J. Cancer102(12), 1731–1735 (2010).
   PubMed Web of Science ®Google Scholar
• Vermaat JS, van der Tweel I, Mehra N et al. Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid a predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. Ann. Oncol.21(7), 1472–1481 (2010).
   PubMed Web of Science ®Google Scholar
• Xu X, Qiao M, Zhang Y et al. Quantitative proteomics study of breast cancer cell lines isolated from a single patient: discovery of TIMM17A as a marker for breast cancer. Proteomics10(7), 1374–1390 (2010).
   PubMed Web of Science ®Google Scholar
• Xue H, Lü B, Zhang J et al. Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J. Proteome Res.9(1), 545–555 (2010).
   PubMed Web of Science ®Google Scholar
• Chang KP, Wu CC, Chen HC et al. Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: potential usage of cystatin A for predicting nodal stage and poor prognosis. Proteomics10(14), 2644–2660 (2010).
   PubMed Web of Science ®Google Scholar
• Tu L, Liu Z, He X et al. Over-expression of eukaryotic translation initiation factor 4 γ 1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. Mol. Cancer9, 78 (2010).
   PubMed Web of Science ®Google Scholar
• Feng XP, Yi H, Li MY et al. Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. Cancer Res.70(9), 3450–3462 (2010).
   PubMed Web of Science ®Google Scholar
• Bauer JA, Chakravarthy AB, Rosenbluth JM et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin. Cancer Res.16(2), 681–690 (2010).
   PubMed Web of Science ®Google Scholar
• Carey MS, Agarwal R, Gilks B et al. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-β pathway signaling indicates response to primary chemotherapy. Clin. Cancer Res.16(10), 2852–2860 (2010).
   PubMed Web of Science ®Google Scholar
• Tabernero J, Cervantes A, Rivera F et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a Phase I dose-escalation study. J. Clin. Oncol.28(7), 1181–1189 (2010).
   PubMed Web of Science ®Google Scholar
• Chung CH, Seeley EH, Roder H et al. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol. Biomarkers Prev.19(2), 358–365 (2010).
   PubMed Web of Science ®Google Scholar
• Amann JM, Lee JW, Roder H et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J. Thorac. Oncol.5(2), 169–178 (2010).
   PubMed Web of Science ®Google Scholar
• An Omics Perspective on Cancer Research. Cho WC (Ed.). Springer, Berlin, Germany (2010).
   Google Scholar
• Cho WC. Proteinchip. In: Encyclopedia of Cancer (Volume 3) (2nd Edition). Schwab M (Ed.). Springer, Berlin, Germany, 2475–2478 (2009).
   Google Scholar